Twist Bioscience (TWST) Receivables (2018 - 2026)

Twist Bioscience (TWST) has reported Receivables for 9 consecutive years, with $81.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables rose 62.67% year-over-year to $81.3 million; the TTM figure through Mar 2026 stood at $81.3 million (up 62.67% YoY), while the FY2025 annual figure was $57.3 million, up 64.2% from the prior year.
• Receivables advanced to $81.3 million in Q1 2026 per TWST's latest filing, from $50.1 million in the prior quarter.
• Across five years, Receivables topped out at $81.3 million in Q1 2026 and bottomed at $32.0 million in Q2 2024.
• Historically, Receivables has averaged $46.7 million across 5 years, with a median of $46.0 million in 2022.
• Annual changes were most pronounced in 2022 — Receivables jumped 1830.51% — and 2024, when it plunged 33.56%.
• Twist Bioscience's Receivables stood at $49.7 million in 2022, then slipped by 28.85% to $35.4 million in 2023, then climbed by 11.2% to $39.3 million in 2024, then rose by 27.34% to $50.1 million in 2025, then surged by 62.3% to $81.3 million in 2026.
• Business Quant data shows TWST's Receivables at $81.3 million in Q1 2026, $50.1 million in Q4 2025, and $57.3 million in Q3 2025.